Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S

Novo Nordisk to reinforce its equity stake in Innate Pharma

Marseille, France and Bagsværd, Denmark, 5 February 2014

• Anti-NKG2A is a first-in-class therapeutic mAb that is Phase II ready
• NKG2A is a NK and T cell checkpoint relevant in both inflammatory disorders and immuno-oncology
• Innate Pharma will prioritize development of anti-NKG2A in immuno-oncology and trials are expected to start in 2014
• Agreement subject to approval by Innate’s shareholders on March 27, 2014

Innate Pharma SA and Novo Nordisk A/S today announce that Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Novo Nordisk conducted a large Phase I safety trial with anti-NKG2A in patients with rheumatoid arthritis, demonstrating a good safety profile for both iv and sc routes at single and multiple administrations. Novo Nordisk has decided to advance other compounds for further development in inflammation, including anti-NKG2D , currently in Phase II development and generated within the collaboration between Innate Pharma and Novo Nordisk.

Novo Nordisk will receive 2 million euros in cash and 600,000 shares for licencing anti-NKG2A to Innate and be eligible to a total of 20 million euros in potential registration milestones and single-digit tiered royalties on future sales. The acquisition of the Innate shares is subject to approval by Innate’s shareholders’ at an extraordinary general meeting on 27 March 2014.

A conference call for fund managers, financial analysts and journalists will be held today at 6:30pm (CET) - Dial in number: +33 (0)1 70 77 09 40.
A replay will be available during three months after the conference call.
Dial in number: +33 (0)1 72 00 15 00 Access number: 285723#.